ResMed Inc, a developer, manufacturer, and distributor of sleep and respiratory medical equipment, released the Narval CC, a mandibular repositioning device.
ResMed’s introduction of Narval CC follows its acquisition of the France-based Laboratoires Narval. With the acquisition, ResMed now has an additional therapy method to complement its positive airway pressure (PAP) solutions, providing a broader offering for snoring and obstructive sleep apnea sufferers.
"The gold-standard therapy for obstructive sleep apnea is PAP therapy,” said Michael Farrell, president, ResMed Americas. “However, we know that today some patients either refuse PAP treatment or fail to comply. Narval CC provides an effective alternative for those untreated patients. With the release of Narval CC, ResMed is now the only PAP company with a customized solution for noncompliant patients or patients who refuse PAP treatment, giving our customers and patients another choice in their treatment."
The cornerstone of the Narval CC design is how it maintains the lower jaw in a forward position with a patented optimized retention of the mandible. This allows natural movement of the jaw, increasing patient comfort, and resulting in superior compliance and efficacy. Each device is custom-made to suit the complex dental anatomy of individual patients using a nimble and scalable computer-aided design and computer-aided manufacturing (CAD/CAM) process.
"Narval CC’s proprietary design combined with CAD/CAM technology offers one of the lightest solutions on the market. Precision-enabled digital dentistry has arrived in the mandibular repositioning device market," said Kristie Burns, general manager, dental sleep, ResMed. "With Narval CC, we finally have a way to reach a previously untreatable patient group with a solution to help them achieve a healthy night’s sleep."
